Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on …